Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

BMC Cancer

Research Article

J. Letreut¹  G. Fraboulet²  G. Oliviero³  R. Lamy⁴  A. Dixmier⁵  G. Robinet⁶  A. Vergnenegre⁷  B. Mastroianni⁸  H. Lena⁹  S. Botta^1,10  J. Mazieres^1,11  H. Berard^1,12  I. Borget^1,13  C. Raynaud^1,14  I. Monnet^1,15  C. Chouaid^1,15  L. Greillier^1,16 

[1] CH Aix en Provence, Aix en Provence, France;CH Cergy Pontoise, Cergy Pontoise, France;CH Longjumeau, Longjumeau, France;CH Lorient, Lorient, France;CH d’Orléans, Orléans, France;CHU Brest, Brest, France;CHU Limoges, Limoges, France;CHU Lyon, Lyon, France;CHU Rennes, Rennes, France;CHU Rouen, Rouen, France;CHU Toulouse, Toulouse, France;HIA Toulon, Toulon, France;IGR, Villejuif, France;Service de Pneumologie, CH Argenteuil, Argenteuil, France;Service de pneumologie, CHI Créteil, 40 avenue de verdun, 94010, Créteil, France;Service d’oncologie thoracique, APHM, Marseille, Services de Pneumologie, Marseille, France;

关键词: Malignant pleural mesothelioma;    Treatment;    Chemotherapy;   

DOI  :  10.1186/s12885-015-1881-x

 received in 2015-01-25, accepted in 2015-10-30,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundMalignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients’ profiles and management in daily practice in France.MethodsObservational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites.ResultsFour hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance (sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in 80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 % response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases.ConclusionsThe management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.

【 授权许可】

CC BY   
© Raynaud et al. 2015